SEARCH

SEARCH BY CITATION

References

  • 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer 2001; 94: 1536.
  • 2
    Herbst RS, Kies MS. ZD1839 (Iressa) in nonsmall cell lung cancer. Oncologist 2002; 7: 915.
  • 3
    Belany C, Eckardt J. Development of docetaxel in advanced nonsmall cell lung cancer. Lung Cancer 2004; 46: S3S11.
  • 4
    NonSmall Cell Lung Cancer Collaborative Group. Chemotherapy in nonsmall cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899909.
  • 5
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced nonsmall cell lung cancer. N Engl J Med 2002; 346: 928.
  • 6
    Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 24150.
  • 7
    Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 244549.
  • 8
    Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall cell lung cancer. J Clin Oncol 2003; 21: 223746.
  • 9
    Suzuki T, Nakagawa T, Endo H, Mitsudomi T, Masuda A, Yatabe Y, Sugiura T, Takahashi T, Hida T. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’) is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer 2003; 42: 3541.
  • 10
    Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 488592.
  • 11
    Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol 2004; 22: 77784.
  • 12
    Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall cell lung cancer: a phase III trial–INTACT 2 Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol 2004; 22: 78594.
  • 13
    Bras-Goncalves RA, Pocard M, Formento JL, Poirson-Bichat F, De Pinieux G, Pandrea I, Arvelo F, Ronco G, Villa P, Coquelle A, Milano G, Lesuffleur T, et al. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis. Gastroenterology 2001; 120: 87488.
  • 14
    de Cremoux P, Tran-Perennou C, Brockdorff BL, Boudou E, Brunner N, Magdelenat H, Lykkesfeldt AE. Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocr Relat Cancer 2003; 10: 40918.
  • 15
    de Cremoux P, Tran-Perennou C, Elie C, Boudou E, Barbaroux C, Poupon MF, De Rycke Y, Asselain B, Magdelenat H. Quantitation of estradiol receptors α and β and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays. Biochem Pharmacol 2002; 64: 50715.
  • 16
    Vogt N, Lefevre S, Apiou F, Dutrillaux A, Cor A, Leuraud P, Poupon MF, Dutrillaux B, Debatisse M, Malfoy B. Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. Proc Natl Acad Sci USA 2004; 101: 1136873.
  • 17
    Vahakangas K, Bennett W, Castren K, Welsh J, Khan M, Blomeke B, Alavanja M, Harris C. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 2001; 61: 43506.
  • 18
    Liang XJ, Shen DW, Garfield S, Gottesman MM. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res 2003; 63: 590916.
  • 19
    Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, Westra WH, Yang SC, Jen J, Sidransky D. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001; 61: 130913.
  • 20
    Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA,Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002; 29: 314.
  • 21
    Kris MG, Natale RB, Herbst RS, Lynch TJ,Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 2003; 290: 214958.
  • 22
    Zhao M, Hartke C, Jimeno A, Li J, He P, Zabelina Y, Hidalgo M, Baker S. Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819: 7380.
  • 23
    Baselga J. Combining the anti-EGFR agent gefitinib with chemotherapy in nonsmall cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 2004; 22: 75961.
  • 24
    Johnson DH. Targeted therapy in nonsmall cell lung cancer: myth or reality. Lung Cancer 2003; 41: S3S8.
  • 25
    Avendano C, Menendez JC. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 2002; 9: 15993.
  • 26
    Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 16504.
  • 27
    Chiou JF, Liang JA, Hsu WH, Wang JJ, Ho ST, Kao A. Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in nonsmall cell lung cancer. Lung 2003; 181: 26773.
  • 28
    Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9S15.
  • 29
    Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002; 7: 319.
  • 30
    Fayette J, Le Chevalier T, Soria JC. Therapeutic implications of epidermal growth factor receptor in lung cancer. Bull Cancer 2003; 90: S233S240.
  • 31
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall cell lung cancer to gefitinib. N Engl J Med 2004; 350: 212939.
  • 32
    Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 29: 29.
  • 33
    Pao W, Wang T, Riely G, Miller V, Pan Q, Ladanyi M, Zakowski MF, Heelan R, Kris MG, Varmus H. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLOS Med 2005; 2: 5761.
  • 34
    Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in nonsmall cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 231626.
  • 35
    Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M. Sensitivity to gefitinib (Iressa, ZD1839) in nonsmall cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004; 3: 46572.
  • 36
    Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese P, Iarussi T, Mucilli F, Mazzetti A, Cuccurullo F, Sacco R, et al. EGFR mutations in nonsmall cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23: 85765.
  • 37
    Kiriakis J, Avruch J. Protein kinase cascades activated by stress and inflammatory cytokines. Bioassays 1996; 18: 56777.
  • 38
    Molton S, Todd D, Cook S. Selective activation of the c-jun N-terminal kinase (JNK) pathway fails to elicit bax activation or apoptosis unless the phosphoinositide 3′- kinase (PI3K) pathway is inhibited. Oncogene 2003; 22: 4690701.
  • 39
    Nelson J, Fry D. Akt, MAPK (Erk1/2) and p38 act in concert to promote apoptosis in response to erbB receptor family inhibition. J Biol Chem 2001; 276: 1484247.
  • 40
    Xia Z, Dickens M, Raingeaud J, Davis R, Greenberg M. Opposing effect of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 132631.